Readoutin 165d
Sanofi — Frexalimab
Phase 3 primary completion: Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis.
- Date
- May 2027
- Type
- Readout
- Indication
- Multiple Sclerosis
Readoutin 165d
Phase 3 primary completion: Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis.
The weekly brief is free. Pro adds reminders 7 days and 1 day before.